Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 Convalescent Plasma in Moderate/Severe COVID-19
NCT04474340Phase 1Unknown
- Sponsor
- Kuwait Ministry of Health
- Start
- May 2020
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Kuwait Ministry of Health. Primary endpoint: Time to clinical improvement at 30 days. Status: unknown.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04474340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04474340.